These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 11049972

  • 1. Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein.
    Ehlert JE, Ludwig A, Grimm TA, Lindner B, Flad HD, Brandt E.
    Blood; 2000 Nov 01; 96(9):2965-72. PubMed ID: 11049972
    [Abstract] [Full Text] [Related]

  • 2. Novel C-terminally truncated isoforms of the CXC chemokine beta-thromboglobulin and their impact on neutrophil functions.
    Ehlert JE, Gerdes J, Flad HD, Brandt E.
    J Immunol; 1998 Nov 01; 161(9):4975-82. PubMed ID: 9794434
    [Abstract] [Full Text] [Related]

  • 3. Connective tissue-activating peptide III desensitizes chemokine receptors on neutrophils. Requirement for proteolytic formation of the neutrophil-activating peptide 2.
    Härter L, Petersen F, Flad HD, Brandt E.
    J Immunol; 1994 Dec 15; 153(12):5698-708. PubMed ID: 7989767
    [Abstract] [Full Text] [Related]

  • 4. The CXC chemokine NAP-2 mediates differential heterologous desensitization of neutrophil effector functions elicited by platelet-activating factor.
    Schwartzkopff F, Brandt E, Petersen F, Flad HD, Bock L, Ludwig A.
    J Interferon Cytokine Res; 2002 Feb 15; 22(2):257-67. PubMed ID: 11911809
    [Abstract] [Full Text] [Related]

  • 5. Thrombin-activated human platelets release two NAP-2 variants that stimulate polymorphonuclear leukocytes.
    Piccardoni P, Evangelista V, Piccoli A, de Gaetano G, Walz A, Cerletti C.
    Thromb Haemost; 1996 Nov 15; 76(5):780-5. PubMed ID: 8950790
    [Abstract] [Full Text] [Related]

  • 6. Platelet-derived chemokines CXC chemokine ligand (CXCL)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration.
    Schenk BI, Petersen F, Flad HD, Brandt E.
    J Immunol; 2002 Sep 01; 169(5):2602-10. PubMed ID: 12193731
    [Abstract] [Full Text] [Related]

  • 7. Molecular cloning and characterisation of a neutrophil chemotactic protein from porcine platelets.
    Power CA, Proudfoot AE, Magnenat E, Bacon KB, Wells TN.
    Eur J Biochem; 1994 Apr 15; 221(2):713-9. PubMed ID: 7513641
    [Abstract] [Full Text] [Related]

  • 8. The amino-terminal residues in the crystal structure of connective tissue activating peptide-III (des10) block the ELR chemotactic sequence.
    Malkowski MG, Lazar JB, Johnson PH, Edwards BF.
    J Mol Biol; 1997 Feb 21; 266(2):367-80. PubMed ID: 9047370
    [Abstract] [Full Text] [Related]

  • 9. The CXC-chemokine neutrophil-activating peptide-2 induces two distinct optima of neutrophil chemotaxis by differential interaction with interleukin-8 receptors CXCR-1 and CXCR-2.
    Ludwig A, Petersen F, Zahn S, Götze O, Schröder JM, Flad HD, Brandt E.
    Blood; 1997 Dec 01; 90(11):4588-97. PubMed ID: 9373270
    [Abstract] [Full Text] [Related]

  • 10. Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III.
    Brandt E, Van Damme J, Flad HD.
    Cytokine; 1991 Jul 01; 3(4):311-21. PubMed ID: 1873479
    [Abstract] [Full Text] [Related]

  • 11. Formation of neutrophil-activating peptide 2 from platelet-derived connective-tissue-activating peptide III by different tissue proteinases.
    Car BD, Baggiolini M, Walz A.
    Biochem J; 1991 May 01; 275 ( Pt 3)(Pt 3):581-4. PubMed ID: 2039437
    [Abstract] [Full Text] [Related]

  • 12. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils.
    Walz A, Dewald B, von Tscharner V, Baggiolini M.
    J Exp Med; 1989 Nov 01; 170(5):1745-50. PubMed ID: 2681518
    [Abstract] [Full Text] [Related]

  • 13. Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets.
    Cohen AB, Stevens MD, Miller EJ, Atkinson MA, Mullenbach G.
    Am J Physiol; 1992 Aug 01; 263(2 Pt 1):L249-56. PubMed ID: 1387511
    [Abstract] [Full Text] [Related]

  • 14. Structural requirements of platelet chemokines for neutrophil activation.
    Yan Z, Zhang J, Holt JC, Stewart GJ, Niewiarowski S, Poncz M.
    Blood; 1994 Oct 01; 84(7):2329-39. PubMed ID: 7919350
    [Abstract] [Full Text] [Related]

  • 15. The beta-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation.
    Brandt E, Petersen F, Ludwig A, Ehlert JE, Bock L, Flad HD.
    J Leukoc Biol; 2000 Apr 01; 67(4):471-8. PubMed ID: 10770278
    [Abstract] [Full Text] [Related]

  • 16. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor.
    Ahuja SK, Murphy PM.
    J Biol Chem; 1996 Aug 23; 271(34):20545-50. PubMed ID: 8702798
    [Abstract] [Full Text] [Related]

  • 17. Identification of distinct surface-expressed and intracellular CXC-chemokine receptor 2 glycoforms in neutrophils: N-glycosylation is essential for maintenance of receptor surface expression.
    Ludwig A, Ehlert JE, Flad HD, Brandt E.
    J Immunol; 2000 Jul 15; 165(2):1044-52. PubMed ID: 10878382
    [Abstract] [Full Text] [Related]

  • 18. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact.
    Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G.
    Blood; 2000 Oct 15; 96(8):2673-81. PubMed ID: 11023497
    [Abstract] [Full Text] [Related]

  • 19. Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. Discrepancies in binding affinities, receptor densities, and biologic effects.
    Petersen F, Flad HD, Brandt E.
    J Immunol; 1994 Mar 01; 152(5):2467-78. PubMed ID: 8133058
    [Abstract] [Full Text] [Related]

  • 20. Structure and bioactivity of recombinant human CTAP-III and NAP-2.
    Proudfoot AE, Peitsch MC, Power CA, Allet B, Mermod JJ, Bacon K, Wells TN.
    J Protein Chem; 1997 Jan 01; 16(1):37-49. PubMed ID: 9055206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.